Chronic Myeloid Leukemia: A Historical Perspective
Chronic Myeloid Leukemia: A Historical Perspective
复制标题
DOI：
10.1053/j.seminhematol.2010.07.001
复制
发表时间：
2010-10-01
影响因子：
3.6
通讯作者：
Goldman, John M.
中科院分区：
文献类型：
--
作者：
Goldman, John M.
1840 年代，法国、德国和苏格兰首次发现了脾肿大和白细胞计数异常高的患者。 19 世纪唯一有据可查的疗法是使用一种或另一种形式的砷，这无疑会减少白细胞计数，但可能对延长生命几乎没有作用或没有作用。这些早期病例可能是慢性粒细胞白血病 (CML)（当时称为慢性粒细胞白血病）的例子。 20 世纪，阐明 CML 发病机制的重要步骤是 1960 年费城染色体的发现和 1973 年 (9;22) 易位的发现。随后 1984 年定义了 22 号染色体上的断点簇区域，并于 1985 年证明了 CML 中的 BCR-ABL 转录本。20 世纪上半叶，患者主要接受放射治疗，后来又采用放射治疗。白消安、羟基脲或干扰素-α (IFN-α)。从1980年起，同种异体干细胞移植（SCT）成为符合条件的患者的首选治疗方法。酪氨酸激酶抑制剂 (TKI) 时代始于 1998 年，如今，最初的 TKI 伊马替尼已取代 SCT 作为慢性期 CML 患者的初始治疗。塞明血液 47：302-311。 (C) 2010 年，爱思唯尔公司出版。
Patients with splenomegaly and abnormally high leukocyte counts were first recognized in France, Germany, and Scotland in the 1840s. The only well-documented therapy in the 19th century was use of arsenic in one or other form, which did undoubtedly reduce the leukocyte count but probably did little or nothing to prolong life. These early cases were probably examples of chronic myeloid leukemia (CML) (then called chronic granulocytic leukemia). In the 20th century important steps in unraveling the pathogenesis of CML were the discovery of the Philadelphia chromosome in 1960, and of the (9;22) translocation in 1973. There followed definition of the breakpoint cluster region on chromosome 22 in 1984 and the demonstration of the BCR-ABL transcript in CML in 1985. In the first half of the 20th century patients were treated predominantly with radiotherapy, and later on with busulfan, hydroxy-carbamide, or interferon-alfa (IFN-alpha). From 1980 onwards allogeneic stem cell transplantation (SCT) became the treatment of choice for eligible patients. The era of tyrosine kinase inhibitors (TKI) began in 1998 and today the use of the original TKI, imatinib, has replaced SCT as initial therapy for patients who present with CML in chronic phase. Semin Hematol 47:302-311. (C) 2010 Published by Elsevier Inc.